Dainippon Sumitomo Pharma Co., Ltd.

37 articles about Dainippon Sumitomo Pharma Co., Ltd.

• 

  Sumitomo Cuts 62 Jobs in NYC Due to Company Consolidation

  7/6/2023

  The layoffs are a result of Sumitomo’s decision announced in April to combine its seven subsidiaries into one company.

• RevolKa Ltd.: Announcement of Milestone Achievement in the Collaborative Research with Sumitomo Pharma Co., Ltd.

  6/23/2023

  RevolKa Ltd., a venture-backed biotech company providing a game-changing protein engineering technology platform is pleased to announce the successful completion of the collaborative drug discovery project with Sumitomo Pharma Co., Ltd. for rare diseases within the contractually agreed time frame.

• Sumitomo Pharma Oncology Presents Preliminary Data from Phase 1/2 Clinical Study Evaluating Investigational Agent TP-3654 in Patients with Myelofibrosis at American Society of Hematology 2022 Annual Meeting & Exposition

  12/10/2022

  Sumitomo Pharma Oncology, Inc. presented new data from the ongoing Phase 1/2 study evaluating TP-3654, an investigational selective oral PIM1 kinase inhibitor, in patients with myelofibrosis previously treated with or ineligible for JAK inhibitor therapy.

• Dainippon Sumitomo Pharma Co., Ltd. Halts Key Phase 3 Global Colorectal Carcinoma Monotherapy Trial

  5/28/2014

• Edison Pharmaceuticals, Inc. Announces Initiation Of EPI-743 Phase 2B/3 Leigh Syndrome Clinical Trial With Dainippon Sumitomo Pharma Co., Ltd. In Japan

  3/10/2014

• Edison Pharmaceuticals, Inc., Dainippon Sumitomo Pharma Co., Ltd. Ink "Biological Energy" Pact Worth $4.3 Billion

  1/31/2014

• Retina Institute Japan and Dainippon Sumitomo Pharma Co., Ltd. Form a Capital Alliance Towards the Development of Nobel Prize Winning iPS Cell Technology

  3/29/2013

• Edison Pharmaceuticals, Inc. Signs Licensing Agreement With Dainippon Sumitomo Pharma Co., Ltd. for Up to $545 Million

  3/28/2013

• Dainippon Sumitomo Pharma Co., Ltd. Sumitomo Seeks SFDA Approval for Cancer Drug

  9/6/2012

• Dainippon Sumitomo Pharma Co., Ltd. Reports that Latuda® (lurasidone HCl) Met Primary and Key Secondary Endpoints in Two Phase III Trials in Bipolar I Depression

  5/7/2012

• Mintz, Levin, Cohn, Ferris, Glovsky and Popeo, P.C’s Life Sciences Practice Represents Boston Biomedical in its Agreement with Dainippon Sumitomo Pharma Co., Ltd. to be Acquired for up to $2.63 Billion

  3/5/2012

• Dainippon Sumitomo Pharma Co., Ltd. Bags Boston Biomedical for $2.6 Billion

  2/29/2012

• Dainippon Sumitomo Pharma Co., Ltd. and Boston Biomedical Enter Strategic Partnership on Anti-Cancer Drugs Targeting Cancer Stem Cells

  4/7/2011

• Dainippon Sumitomo Pharma Co., Ltd. and Intercept Pharmaceuticals Announce Agreement to Develop and Commercialize Obeticholic Acid (INT-747) for Chronic Liver Disease; Dainippon Pays Intercept $15 Million and up to $300 Million

  3/30/2011

• Codexis Pharmaceuticals Signs First Japanese Biocatalysis Collaboration With Dainippon Sumitomo Pharma Co., Ltd.

  1/25/2011

• Dainippon Sumitomo Pharma Co., Ltd.'s Sunovion Pharmaceuticals Inc.'s Schizophrenia Pill, Latuda Gets FDA Nod

  10/29/2010

• Dainippon Sumitomo Pharma Co., Ltd. and SanBio, Inc. Collaborate on Cell Therapy for Stroke Recovery

  10/4/2010

• Sepracor, Inc., Subsidiary of Dainippon Sumitomo Pharma Co., Ltd., Fails to Win U.S. Approval of Epilepsy Drug STEDESA

  5/4/2010

• Silence Therapeutics plc and Dainippon Sumitomo Pharma Co., Ltd. Expand siRNA Delivery Collaboration

  3/30/2010

• Dainippon Sumitomo Pharma Co., Ltd. and Sepracor, Inc. Announce Completion of Subsequent Offering Period and Exercise of Top-Up Option

  10/20/2009